touchPANEL DISCUSSION

Tailoring treatment in myelofibrosis: Addressing anaemia and thrombocytopenia

Access to this content is not permitted for healthcare professionals based in the US and UK.

Back to CME

This activity is for healthcare professionals outside of the USA and UK.

This activity is funded by an independent medical education grant from GSK.

This activity is provided by touchIME in collaboration with our Education Partner Haematology Nurses & Healthcare Professionals Group (HNHCP).

touchIME is an EBAC® accredited provider.

Faculty & Disclosures

Listen on the go

    • View and download resources from this activity to support your learning and share with colleagues. Select a language to continue.

    Downloads
    Download Slides
    Download Practice Aid
    Download Slides
    CORRECT!
    Next question
    Faculty & Disclosures
    Prof. Haifa Kathrin Al-Ali

    University Hospital of Halle, Halle (Saale), Germany

    Haifa Kathrin Al-Ali is a professor of translational oncology and the director of the Krukenberg Cancer Center at the University Hospital of Halle (Saale), Halle, Germany. read more

    Prof. Al-Ali is a senior consultant in internal medicine, haematology and oncology. The scientific focus of her work has been in the field of myeloid malignancies – myeloproliferative neoplasms (MPN), myelodysplastic syndromes and acute myeloid leukaemia. Her research has focused on the implementation of phase I–IV clinical and translational studies, and the investigation of the relevance of genetic and epigenetic changes in myeloid diseases and predictive factors of response. Prof. Al-Ali’s research has been published in journals such as The New England Journal of Medicine, Blood, and Leukemia. She is also a member of the steering committee for the MPN Hub.

    Prof. Haifa Kathrin Al-Ali discloses: Advisory board or panel fees from AOP Pharma, Bristol Myers Squibb, GSK, Incyte, MSD and Novartis. Consultant fees from AbbVie, AOP Pharma, Blueprint, Bristol Myers Squibb, GSK, MSD, Novartis, Otsuka and Stemline. Grants/research support from Bristol Myers Squibb and Incyte. Other financial or material support (royalties, patent, etc.) from AbbVie and Alexion.
    Prof. Jean-Jacques Kiladjian

    Université Paris Cité and Saint-Louis Hospital, Paris, France

    Jean-Jacques Kiladjian is professor of clinical pharmacology at Université Paris Cité and consultant haematologist and head of the Clinical Investigation Center of the Saint-Louis Hospital, Paris, France. read more

    Prof. Kiladjian’s research has centred on myeloproliferative neoplasms and myelodysplastic syndromes. In these disorders, he has been very active in evaluating novel therapeutics and implementing clinical trials. He is an active member of many societies including the European Hematology Association (EHA), the American Society of Hematology (ASH), the European LeukemiaNet and the European School of Haematology. Since 2008, Prof. Kiladjian has been the president of the French Intergroup of Myeloproliferative disorders. He has provided educational lectures in several French and international meetings over the years, including at ASH, EHA and the American Society of Clinical Oncology annual meetings. He is published in many peer-reviewed journals, including The New England Journal of Medicine, Journal of Clinical Oncology, Blood, Lancet Haematology, Leukemia, etc., and has authored several book chapters. He is associate editor of Leukemia, European Journal of Haematology, HemaSphere, Hemato.

    Prof. Jean-Jacques Kiladjian discloses: Advisory board or panel fees from AOP Health and Incyte. Consultant fees from AbbVie, Bristol Myers Squibb, GSK and Novartis.
    Prof. Alessandro Vannucchi

    University of Florence, Florence, Italy

    Alessandro Vannucchi is a full professor of haematology, founder of the Center Research and Innovation of Myeloproliferative Neoplasms and director of the haematology and oncology departments at the University of Florence and Azienda Ospedaliera Universitaria Careggi in Florence, Italy. read more

    Prof. Vannucchi holds various appointments at the University of Florence, including director of the Postgraduate School in Hematology and director of the Center for High Education “DenoTHE”. His main research interests are myeloproliferative neoplasms (MPNs) and molecular genetics of myeloid neoplasia, including leukaemia. He has been the principal investigator of more than 70 clinical trials.

    Prof. Vannucchi serves as chair of the GIMEMA Foundation Working Party on MPN and is the principal investigator of the Italian MyNERVA research alliance on MPN and related myeloid disorders. Prof. Vannucchi sits on the board of the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT), the European LeukemiaNet Work Package 9 for MPN and the European Hematology Association Specialized Working Group on Myeloproliferative Neoplasms. He is currently the president of the Italian Society of Experimental Hematology. Prof. Vannucchi has authored and co-authored more than 660 peer-reviewed publications, mostly in the field of MPN, and presented communications and invited lectures at national and international meetings.

    Since 2017, Prof. Vannucchi has been listed among the Highly Cited Researchers in Clinical Medicine – Web of Science, Highly Ranked ScholarGPS, and the 100 Top Italian Scientists. In 2023, he received the honour of Commander of Merit by the President of the Republic of Italy for his scientific achievements.

    Prof. Alessandro Vannucchi discloses: Advisory board or panel fees from AbbVie, AOP Orphan Pharmaceuticals, Blueprint, Bristol Myers Squibb, Celgene, Constellation, CTI BioPharma, Geron, GSK, Imago, Incyte, iOnctura, Italfarmaco, Kartos, Karyopharm, Keros, MorphoSys, Novartis, Protagonist, Roche and Sierra.
    Back to Faculty
    touchHAEMATOLOGY touchHAEMATOLOGY
    Start activity

    Tutorial

    These icons indicate there is something to be interacted with. Click it when you see it.

    Poll

    In your opinion what is the most important strategy to maximize the success of JAK inhibitor treatment in your patients with myelofibrosis?

    Submit your answer to see the results

    Patient education
       
    Regular monitoring for treatment response
       
    Early treatment initiation
       
    Other
       

    Tutorial

    These icons indicate there is something to be interacted with. Click it when you see it.

    Poll

    What is your most important consideration when selecting a JAK inhibitor for your patients with myelofibrosis and cytopenias?

    Submit your answer to see the results

    Patients’ comorbidities
       
    Impact on cytopenias
       
    Tolerability and side effects
       
    Other
       

    Tutorial

    These icons indicate there is something to be interacted with. Click it when you see it.

    Poll

    What is the biggest challenge for your patients with myelofibrosis and cytopenias?

    Submit your answer to see the results

    Fatigue and physical strain
       
    The burden of transfusions
       
    The impact on QoL
       
    Other
       
     
    Videos Take CE/CME Test
    Myeloproliferative Disorders, Anaemia, Rare Diseases, Thrombocytopenia CE/CME accredited

    touchPANEL DISCUSSION
    A visually engaging discussion designed to emulate a ‘live’ panel experience and provide clinicians with practical expert insights to address their clinical challenges. Useful tips below will show how to navigate the activity. Close

    Tailoring treatment in myelofibrosis: Addressing anaemia and thrombocytopenia

    Faculty Podcast Featured
    Useful tips
    • Select in the video player controls bar to choose subtitle language. Subtitles available in English, French, German, Italian, Japanese, Portuguese, Spanish.
    • A practice aid is available for this activity in the Toolkit
    • Downloads including slides are available for this activity in the Toolkit
    Learning Objectives

    After watching this activity, participants should be better able to:

    • Evaluate the burden of disease and QoL impact for patients with myelofibrosis and anaemia and/or thrombocytopenia and the importance of early treatment initiation
    • Assess the current management strategies for patients with myelofibrosis and anaemia and/or thrombocytopenia and the impact on patient outcomes, including QoL
    • Review the emerging treatment options for managing patients with myelofibrosis, and other strategies to optimize outcomes
    Overview

    In this activity, three leading experts discuss the burden of myelofibrosis and anaemia and/or thrombocytopenia before reviewing approved and emerging targeted treatment options and strategies to maximize benefits for patients. read more

    Target Audience

    This activity has been designed to meet the educational needs of haematologists, including haemato-oncologists, hospital pharmacists and haematology nurses involved in the management of patients with myelofibrosis and anaemia and/or thrombocytopenia.

    EBAC® Accreditation

    touchIME is an EBAC® accredited provider since 2023.

    This programme is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 49 minutes of effective education time.

    The Accreditation Council for Continuing Medical Education (ACCME) and the Royal College of Physicians and Surgeons of Canada hold an agreement on mutual recognition on substantive equivalency of accreditation systems with EBAC®.

    Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association (AMA), physicians may convert EBAC® CE credits to AMA PRA Category 1 CreditsTM. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other healthcare professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 CreditTM.

    Faculty Disclosure Statement / Conflict of Interest Policy

    In compliance with EBAC® guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest, which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event have been mitigated and declared to the audience prior to the CME activities.

    Faculty

    Prof. Haifa Kathrin Al-Ali discloses: Advisory board or panel fees from AOP Pharma, Bristol Myers Squibb, GSK, Incyte, MSD and Novartis. Consultant fees from AbbVie, AOP Pharma, Blueprint, Bristol Myers Squibb, GSK, MSD, Novartis, Otsuka and Stemline. Grants/research support from Bristol Myers Squibb and Incyte. Other financial or material support (royalties, patent, etc.) from AbbVie and Alexion.

    Prof. Jean-Jacques Kiladjian discloses: Advisory board or panel fees from AOP Health and Incyte. Consultant fees from AbbVie, Bristol Myers Squibb, GSK and Novartis.

    Prof. Alessandro Vannucchi discloses: Advisory board or panel fees from AbbVie, AOP Orphan Pharmaceuticals, Blueprint, Bristol Myers Squibb, Celgene, Constellation, CTI BioPharma, Geron, GSK, Imago, Incyte, iOnctura, Italfarmaco, Kartos, Karyopharm, Keros, MorphoSys, Novartis, Protagonist, Roche and Sierra.

    Touch Medical Contributors

    Katrina Lester has no financial interests/relationships or affiliations in relation to this activity.

    Requirements for Successful Completion

    Certificates of Completion may be awarded upon successful completion of the post-test and evaluation form. If you have completed one hour or more of effective education through EBAC® accredited CE activities, please contact us at accreditation@touchime.org to receive your EBAC® CE credit certificate. EBAC® grants 1 CE credit for every hour of education completed.

    Date of original release: 14 April 2025. Date credits expire: 14 April 2027.

    Time to complete: 49 minutes

    If you have any questions regarding the EBAC® credits, please contact accreditation@touchime.org  

     

    This activity is CE/CME accredited

    To obtain the CE/CME credit(s) from this activity, please complete this post-activity test.

    Claim Credit
    Useful tips
    • Select in the video player controls bar to choose subtitle language. Subtitles available in English, French, German, Italian, Japanese, Portuguese, Spanish.
    • A practice aid is available for this activity in the Toolkit
    • Downloads including slides are available for this activity in the Toolkit

    You may also be interested in...

    CONFERENCE HUB

    Bridging the gap in paediatric sickle cell care: Expanding transplant access globally

    GO TO HUB

    touchSYMPOSIUM

    Collaboration in chronic ITP: Improving quality of life and patient outcomes

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    touchIN CONVERSATION

    Optimizing outcomes of JAK inhibition in myelofibrosis: Practical considerations for the clinic

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Marina Kremyanskaya, EHA 2023: Findings of the REVIVE study of rusfertide in polycythaemia vera

    GO TO HUB
    Red blood cell artwork

    JOURNALS

    Sutimlimab potently inhibits the classical complement pathway, with efficacy against cold agglutinin disease

    GO TO ARTICLE
    red blood cells

    JOURNALS

    Coming in from the cold: The phase III CASCADE trial of pegcetacoplan in cold agglutinin disease

    GO TO ARTICLE

    Topics covered in this activity

    Myeloproliferative Disorders / Anaemia / Rare Diseases / Thrombocytopenia
    REGISTER NOW FOR FREE ACCESS TO
    • 1000+ topical and insightful peer-reviewed journal articles
    • 100+ hours of bite-sized congress highlights
    • 10 major therapy areas packed with the latest scientific advances
    • 150+ specialties offering learn-on-the-go medical education
    • + Concise email updates and newsletters so you never miss out
    Register For Free Now
    This activity is funded by:

    An independent medical education grant from GSK.

    This activity is provided by touchIME in collaboration with our Education Partner Haematology Nurses & Healthcare Professionals Group (HNHCP).

    touchIME is an EBAC® accredited provider.

    EBAC®

    touchIME is an EBAC® accredited provider since 2023.

    In compliance with EBAC® guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.

    This content is intended for healthcare professionals outside the UK and USA.

    Date of original release: 10 April 2025. Date credits expire: 10 April 2027.

    Claim Credit
    touchPANEL DISCUSSION
    Tailoring treatment in myelofibrosis: Addressing anaemia and thrombocytopenia
    0.75 CE/CME credit
    Question 1/5
    In a global study that investigated the QoL impact of anaemia and transfusion dependence in patients with symptomatic MF, what percentage of patients reported frequent transfusions as inconvenient?

    MF, myelofibrosis; QoL, quality of life.

    A multinational, cross-sectional, online survey study was carried out between October 2023 and February 2024 in patients with MF from the US, UK, Germany, Italy, Spain, and Poland (N=155) to assess the associated QoL impact of anaemia and transfusion dependence. Patients were symptomatic and previously treated with a JAK inhibitor. Overall, 59% of patients reported frequent transfusions to be “extremely” or “quite a bit” inconvenient. The most common inconveniences reported were time spent at the clinic (81%), travel time (40%) and scheduling issues (32%).

    Abbreviations
    JAK, Janus kinase; MF, myelofibrosis; QoL, quality of life.

    Reference
    LeBlanc TW, et al. Blood. 2024;144(Suppl. 1):3815.

    Question 2/5
    Your patient is diagnosed with symptomatic MF and anaemia. You recommend starting treatment with a JAK inhibitor. Your patient asks about expected outcomes associated with treatment. In addition to the reported improvements in constitutional symptoms and splenomegaly, what might you tell them about JAK inhibitor treatment?

    JAK, Janus kinase; MF, myelofibrosis.

    The JAK inhibitors ruxolitinib and fedratinib improve constitutional symptoms and splenomegaly, but carry on-target risks of worsening anaemia and thrombocytopenia, limiting their use in patients with cytopenic MF.1

    Momelotinib is approved for disease-related splenomegaly or symptoms in adults with moderate-to-severe anaemia and primary MF, PPV-MF or PET-MF.2 Post hoc analyses of data from the pivotal phase III SIMPLIFY-1, -2 and MOMENTUM trials showed that relative to ruxolitinib, momelotinib was an effective treatment for patients with MF and moderate-to-severe thrombocytopenia.3 Pacritinib is FDA-approved for adults with intermediate or high-risk primary or secondary MF with a PC <50 x 109/L,4 and has demonstrated spleen and symptom reduction in patients with MF regardless of cytopenias.5

    Abbreviations
    FDA, US Food and Drug Administration; JAK, Janus kinase; MF, myelofibrosis; PC, platelet count; PET, post-essential thrombocythaemia; PPV, post-polycythaemia vera.

    References

    1. Reynolds SB, Pettit K. Hematology Am Soc Hematol Educ Program. 2022;2022:235–44.
    2. EMA. Momelotinib SmPC. Available at: https://bit.ly/4c5jzAE (accessed 27 March 2025).
    3. Kiladjian J-J, et al. Hemasphere. 2023;7:e963.
    4. FDA. Pacritinib PI. Available at: https://bit.ly/4j3auKK (accessed 27 March 2025).
    5. Bose P, et al. J Clin Oncol. 2023;41(Suppl. 16):7068.
    Question 3/5
    Your patient was diagnosed with high-risk primary MF and mild anaemia (Hb 9.8 g/dL) and thrombocytopenia (PC 120 x 109/L). Ruxolitinib treatment demonstrated an initial spleen response, but after 8 months of treatment, your patient developed transfusion-dependent anaemia (Hb 7.0 g/dL) and worsening thrombocytopenia (PC 58 x 109/L). Their ruxolitinib dose was reduced accordingly. Three months later, your patient reports persistent fatigue and splenic discomfort (palpable 10 cm below LCM); PC 49 x 109/L and Hb 7.9 g/dL. What would you recommend to best manage this patient?

    ESA, erythropoiesis-stimulating agent; Hb, haemoglobin; LCM, left costal margin; MF, myelofibrosis; PC, platelet count.

    Momelotinib represents a tolerable and effective treatment option for patients with moderate-to-severe anaemia and primary MF, as well as in patients with moderate-to-severe thrombocytopenia.1,2 Patients with MF and a PC <50 x 109/L should not be treated with ruxolitinib or fedratinib.3,4

    Abbreviations
    MF, myelofibrosis; PC, platelet count.

    References

    1. EMA. Momelotinib SmPC. Available at: https://bit.ly/4c5jzAE (accessed 27 March 2025).
    2. Kiladjian J-J, et al. Hemasphere. 2023;7:e963.
    3. EMA. Ruxolitinib SmPC. Available at: https://bit.ly/41UP8Zi (accessed 27 March 2025).
    4. EMA. Fedratinib SmPC. Available at: https://bit.ly/4iYRkpx (accessed 27 March 2025).
    Question 4/5
    In a retrospective real-world study in patients with MF in the United States, what was the 1-year OS probability associated with pacritinib treatment?

    MF, myelofibrosis; OS, overall survival.

    In a study assessing real-world treatment patterns and outcomes in patients with MF treated with pacritinib in the United States, 1-year OS probability was 69.4%.1 Pacritinib is FDA-approved for patients with intermediate or high-risk primary or secondary MF and a PC <50 x 109/L.2 It is in phase III development in Europe and other countries.3

    Abbreviations
    FDA, US Food and Drug Administration; MF, myelofibrosis; OS, overall survival; PC, platelet count.

    References

    1. Marrone M, et al. J Clin Oncol. 2024;42(Suppl. 16):6579.
    2. FDA. Pacritinib PI. Available at: https://bit.ly/4j3auKK (accessed 27 March 2025).
    3. ClinicalTrials.gov. NCT03165734. Available at: https://bit.ly/4i2rCzL (accessed 27 March 2025).
    Question 5/5
    You have initiated JAK inhibitor treatment in your patient with MF. How would you best monitor for treatment response to inform the need for potential changes to their treatment plan?

    JAK, Janus kinase; LCM, left costal margin; MF, myelofibrosis; PC, platelet count; PRO, patient-reported outcome; WBC, white blood cell.

    According to recommendations from a global consensus group, response to JAK inhibitor treatment in patients with MF should be measured every 3–6 months depending on MF risk category and stability. Assessments should include, but are not limited to, accurately determined spleen size, e.g. using a measuring tape; and assessing symptom score with a validated tool, e.g. MPN-SAFTSS or MFSAF.

    Abbreviations
    JAK, Janus kinase; MF, myelofibrosis; MFSAF; MF Symptom Assessment Form; MPN-SAFTSS, Myeloproliferative Neoplasm SAF Total Symptom Score.

    Reference
    Koschmieder S, et al. Leukemia. 2024;38:1831–8.

    Back to Activity

    You may also be interested in...

    touchPANEL DISCUSSION

    Tailoring treatment in myelofibrosis: Addressing anaemia and thrombocytopenia

    This activity is CE/CME accredited
    LAUNCH ACTIVITY
    Combination Therapy in Myelofibrosis: John Mascarenhas on the IMpactMF trial

    CONFERENCE HUB

    Navtemadlin in myelofibrosis: Advancing treatment with MDM2 inhibition

    GO TO HUB

    touchIN CONVERSATION

    Optimizing outcomes of JAK inhibition in myelofibrosis: Practical considerations for the clinic

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Srdan Verstovsek: Challenges and emerging therapies in myelofibrosis

    GO TO HUB
    Red blood cell artwork

    JOURNALS

    Sutimlimab potently inhibits the classical complement pathway, with efficacy against cold agglutinin disease

    GO TO ARTICLE
    red blood cells

    JOURNALS

    Coming in from the cold: The phase III CASCADE trial of pegcetacoplan in cold agglutinin disease

    GO TO ARTICLE
    This activity is funded by:

    An independent medical education grant from GSK.

    This activity is provided by touchIME in collaboration with our Education Partner Haematology Nurses & Healthcare Professionals Group (HNHCP).

    touchIME is an EBAC® accredited provider.

    EBAC®

    touchIME is an EBAC® accredited provider since 2023.

    In compliance with EBAC® guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.

    This content is intended for healthcare professionals outside the UK and USA.

    Date of original release: 10 April 2025. Date credits expire: 10 April 2027.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup